Article Details

This small biotech notched a big win for rare disease patients with a canny market access strategy

Retrieved on: 2024-12-19 15:45:23

Tags for this article:

Click the tags to see associated articles and topics

This small biotech notched a big win for rare disease patients with a canny market access strategy. View article details on hiswai:

Summary

The article highlights biotechnology advancements in treating IgA nephropathy, a rare kidney autoimmune disease. Using the orphan drug pathway, TARPEYO (budesonide) emerged as a key treatment, addressing chronic kidney disease and other related conditions.

Article found on: clarivate.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up